a Therapeutics(US:COYA)2026-03-16 12:07Financial Performance - Coya Therapeutics reported a net loss of $21.2 million for the year ended December 31, 2025, compared to a net loss of $14.9 million for 2024, reflecting an increase of approximately 42%[11] - Net loss for 2025 was $21,226,107, compared to a net loss of $14,880,787 in 2024, indicating a significant increase in losses[23] - Net cash used in operating activities was $10,739,301 in 2025, slightly higher than $10,288,822 in 2024[23] Revenue and Collaboration - Collaboration revenues increased to $7.9 million in 2025 from $3.6 million in 2024, primarily due to a $3.6 million rise in license revenue[7] - Proceeds from the sale of common stock in 2025 amounted to $20,348,653, compared to $14,004,381 in 2024, showing a growth of about 45%[23] - Net cash provided by financing activities was $20,386,927 in 2025, an increase from $16,026,816 in 2024[23] Research and Development - Research and development (R&D) expenses rose to $16.7 million in 2025, up from $11.9 million in 2024, driven by increased clinical expenses related to COYA 302[8] - In-process research and development expenses were $2.3 million for 2025, compared to $0 for 2024, due to milestone payments related to the IND acceptance[9] - In-process research and development costs in accrued expenses were $1,125,000 in 2025, indicating ongoing investment in R&D[23] Cash and Assets - Coya had cash and cash equivalents of $46.8 million as of December 31, 2025, compared to $38.3 million at the end of 2024[6] - Cash and cash equivalents at the end of 2025 were $46,822,786, up from $38,339,762 at the end of 2024, representing an increase of approximately 22%[23] - The net increase in cash and cash equivalents for 2025 was $8,483,024, compared to $5,712,994 in 2024, reflecting improved cash flow management[23] - Coya's total assets increased to $49.95 million as of December 31, 2025, from $44.35 million in 2024[19] Expenses - General and administrative expenses increased to $11.4 million in 2025 from $8.9 million in 2024, primarily due to higher payroll and professional service fees[10] - Stock-based compensation increased to $4,290,315 in 2025 from $2,663,539 in 2024, reflecting a rise of approximately 61%[23] - The company incurred $1,164,602 in cash used for the purchase of in-process research and development assets in 2025, compared to $25,000 in 2024[23] Clinical Trials and Regulatory - Coya is actively enrolling patients in the ALSTARS Phase 2 trial for COYA 302 across approximately 25 clinical sites in the U.S. and Canada[2] - The company received FDA acceptance of its IND application for COYA 302 for the treatment of frontotemporal dementia (FTD)[2] Collaboration Receivables - The company reported a decrease in collaboration receivable from $7,500,000 in 2024 to $0 in 2025[23]